Asthma Drugs
Publication Date
February 2024
USD 18.84 billion
USD 33.59 billion
USD 20.44 billion
Asthma Drugs Market by Product (Long-Term Control Medications, Medications for Allergy-Induced Asthma, Quick-Relief Medications (Rescue Medications)), Application (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030

[195 Pages Report] The Asthma Drugs Market size was estimated at USD 18.84 billion in 2023 and expected to reach USD 20.44 billion in 2024, at a CAGR 8.61% to reach USD 33.59 billion by 2030.

Asthma Drugs Market
To learn more about this report, request a free sample copy
Asthma drugs encompass a varied range of medical treatments designed specifically to manage and alleviate the symptoms of asthma, a chronic respiratory condition. These drugs work by opening the lung airways or reducing inflammation, thereby preventing or reducing the frequency of asthma attacks. The category includes a broad spectrum of medications such as bronchodilators, inhaled corticosteroids, leukotriene modifiers, and more, each targeting different aspects of asthma control. The increasing prevalence of asthma, spurred by rising air pollution levels and genetic predispositions, primarily drives the growth. Growing awareness and better diagnosis rates in emerging economies also contribute to the demand for asthma medications. Additionally, advancements in drug formulations and delivery methods have further propelled the development. However, the asthma drugs market faces several challenges, including high costs associated with new and advanced medications, making them inaccessible to lower-income populations. Moreover, side effects associated with the long-term use of certain asthma drugs can also deter their adoption. There is also the pressing issue of medication adherence amongst patients, impacting the overall efficacy of treatment. Furthermore, the development of personalized medicine approaches aims to tailor treatments based on individual patient genetics and disease phenotype, offering lucrative opportunities. Innovation in biological therapies presents another significant opportunity, offering the potential for treatments with fewer side effects and better outcomes. Expanding markets in developing regions and increasing investment in asthma research also provide notable prospects for growth.
Asthma Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Asthma Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Asthma Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Asthma Drugs Market, highlighting leading vendors and their innovative profiles. These include ALK-Abelló A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hetero Labs Limited, Lallemand Inc., Merck KGaA, Mundipharma International Limited, NIOX Group PLC, Novartis AG, OPKO Health, Inc., Sanner GmbH, Sanofi S.A., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Verona Pharma PLC, and Viatris, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Long-Term Control Medications
    • Medications for Allergy-Induced Asthma
    • Quick-Relief Medications (Rescue Medications)
  • Application
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Asthma Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Asthma Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Asthma Drugs Market?
  4. What is the market share of the leading vendors in the Asthma Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Asthma Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Asthma Drugs Market, by Product
  7. Asthma Drugs Market, by Application
  8. Americas Asthma Drugs Market
  9. Asia-Pacific Asthma Drugs Market
  10. Europe, Middle East & Africa Asthma Drugs Market
  11. Competitive Landscape
  12. Competitive Portfolio
Companies Mentioned
  • ALK-Abelló A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Lallemand Inc.
  • Merck KGaA
  • Mundipharma International Limited
  • NIOX Group PLC
  • Novartis AG
  • OPKO Health, Inc.
  • Sanner GmbH
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • Viatris, Inc.
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Asthma Drugs Market
The Global Asthma Drugs Market size was estimated at USD 18.84 billion in 2023 and expected to reach USD 20.44 billion in 2024.
The Global Asthma Drugs Market to grow USD 33.59 billion by 2030, at a CAGR of 8.61%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.